Boston Scientific (NYSE:BSX) Updates Q1 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its first quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.780-0.800 for the period, compared to the consensus estimate of 0.790. The company issued revenue guidance of $5.1 billion-$5.2 billion, compared to the consensus revenue estimate of $5.2 billion. Boston Scientific also updated its FY 2026 guidance to 3.430-3.490 EPS.

Wall Street Analyst Weigh In

BSX has been the subject of several analyst reports. BTIG Research reissued a “buy” rating on shares of Boston Scientific in a report on Wednesday. The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a report on Thursday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, January 21st. Barclays decreased their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Morgan Stanley decreased their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $110.36.

Boston Scientific Stock Performance

Shares of Boston Scientific stock traded up $2.69 during trading on Thursday, reaching $78.19. The company’s stock had a trading volume of 25,667,993 shares, compared to its average volume of 16,035,756. Boston Scientific has a 52 week low of $74.86 and a 52 week high of $109.50. The business’s 50-day moving average price is $94.37 and its 200-day moving average price is $99.13. The firm has a market cap of $115.91 billion, a PE ratio of 41.83, a P/E/G ratio of 1.63 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the firm posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities analysts forecast that Boston Scientific will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by company insiders.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat consensus: BSX reported $0.80 EPS and ~$5.29B in revenue with ~16% reported sales growth — the underlying quarter is strong and supports the longer‑term growth narrative. PR Newswire — Q4 results
• Positive Sentiment: Analysts trimmed price targets but largely maintained buy/overweight/outperform ratings — many brokers lowered PTs after the call while still signaling upside, which can attract dip buyers. Benzinga — analyst reactions
• Neutral Sentiment: Unusual options activity and trading strategies are in play (including strangle strategies highlighted among top active option names); this increases intraday volatility but is not a fundamental change. Barchart — options activity
• Neutral Sentiment: Long-term research pieces continue to highlight BSX as a growth name (Zacks and others), supporting buy-and-hold investors despite near-term noise. Zacks — long-term view
• Negative Sentiment: Soft FY‑2026 and Q1 guidance from BSX drove a large selloff when released — management’s cautious revenue and EPS outlook remains the principal near‑term risk to the stock’s multiple. Reuters — guidance reaction
• Negative Sentiment: Multiple broker price‑target reductions were published today (examples include RBC, Morgan Stanley, Evercore, Wells Fargo and others), which can keep sentiment muted even though many ratings remain bullish. StreetInsider — PT changes
• Negative Sentiment: Insider selling: CEO Michael Mahoney disclosed a large sale (~160,901 shares) earlier this week, which can be viewed negatively by short‑term traders. SEC filing — insider sale

Institutional Investors Weigh In On Boston Scientific

Several hedge funds have recently added to or reduced their stakes in the business. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter worth about $26,000. Pin Oak Investment Advisors Inc. bought a new position in Boston Scientific during the 3rd quarter worth $41,000. Johnson Financial Group Inc. boosted its holdings in shares of Boston Scientific by 196.4% in the third quarter. Johnson Financial Group Inc. now owns 735 shares of the medical equipment provider’s stock valued at $72,000 after acquiring an additional 487 shares in the last quarter. Seldon Capital LP purchased a new position in Boston Scientific in the 2nd quarter worth about $208,000. Finally, Victory Financial Group LLC increased its holdings in Boston Scientific by 14.3% in the third quarter. Victory Financial Group LLC now owns 2,216 shares of the medical equipment provider’s stock worth $216,000 after buying an additional 278 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.